Talazoparib plus enzalutamide shows improvement in PFS over SOC in first-line HRR mCRPC

mCRPC Care: Reducing Progression Risk by Combining Enzalutamide and TalazoparibПодробнее

TALAPRO-2 Study Design for 1L in mCRPC Patients - NOW FDA Approved | #oncology #cancer #2023Подробнее

TALAPRO-2: exploratory analyses of HRR gene subgroups in mCRPCПодробнее

TALAPRO-2: rPFS and OS of talazoparib and enzalutamide in mCRPCПодробнее

TALAPRO-2 Study of Talazoparib/Enzalutamide in Prostate Cancer: Stephen Freedland and Neeraj AgarwalПодробнее

TALAPRO-2: Phase 3 Results of Talazoparib Plus Enzalutamide for mCRPCПодробнее

CASPAR: the addition of rucaparib to enzalutamide for the treatment of mCRPCПодробнее

Dr. Agarwal on the Safety Profile of Enzalutamide/Talazoparib in mCRPCПодробнее

Novel combination therapy regimen shows promising results for prostate cancerПодробнее

ARROW: PSMA-targeted radioligand therapy plus enzalutamide in mCRPCПодробнее

New FDA Approved PARP Inhibitor: Talzenna (Talazoparib) & Xtandi | #markscholzmd #AlexScholz #pcriПодробнее

TALAPRO-2: exposure efficacy of talazoparib and enzalutamide in mCRPCПодробнее

Treatment sequencing in mCRPC: cabazitaxel vs. abiraterone or enzalutamideПодробнее

PROfound performance: olaparib vs. enzalutamide or abiraterone for HRR altered mCRPCПодробнее

Talazoparib Plus Enzalutamide: TALAPRO-2 Results and Subset AnalysesПодробнее

Updates from the CHEIRON study: docetaxel plus enzalutamide for mCRPCПодробнее

Dr. Pal on Sequencing Abiraterone and Enzalutamide in mCRPCПодробнее

ENZAMET trial: Early enzalutamide delays progression, improves survival in mHSPCПодробнее

RAMP: Phase Ib study of rucaparib & enzalutamide in mCRPCПодробнее